11.10.2010
- Sanofi-Aventis denied that it had dangled a higher price for Genzyme before going hostile with its $18.5 billion bid, deepening the animosity in their transatlantic takeover fight...
11.10.2010
- French drugmaker Sanofi-Aventis, faced with looming generic competition for its top-selling product, said on Friday it was cutting its U.S. pharmaceutical operations by about 25%...
08.10.2010
- Genzyme said that Sanofi-Aventis's chief executive had privately opened the door in September to paying as much as $80 per share for the U.S. company before going hostile with a...
07.10.2010
- Sanofi-Aventis finally made a hostile $18.5 billion tender offer for Genzyme, but it acknowledged that Genzyme's willingness, and possibly a higher price, may be needed to succeed...
04.10.2010
- French drugmaker Sanofi-Aventis launched a hostile bid for Genzyme at $69 per share, or $18.5 billion, setting off what could be a protracted battle for control of the U.S. biotech...
28.09.2010
- Sanofi-Aventis has not changed its offer of $69 per share for drugmaker Genzyme, a Sanofi spokesman said Monday, declining to comment on a report it may be lining up more funding...
22.09.2010
- Novo Nordisk's experimental ultra-long-acting insulin degludec is up to four times less variable in its day-to-day effect than Sanofi-Aventis's established rival Lantus, data on...
20.09.2010
- An oil major, a luxury cosmetics company and independent directors including a former astronaut will have a key say in what may be the next multi-billion dollar merger to shake the...
